This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Top Research Reports for Netflix, Eli Lilly & United Parcel Service
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Eli Lilly (LLY) and United Parcel Service (UPS).
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
by Zacks Equity Research
Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty
by Benjamin Rains
Check out these three dividend-paying stocks that investors might want to buy to help combat coronavirus-based market pullback fears...
Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study
by Zacks Equity Research
Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.
Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.
Bayer Seeks FDA Approval for New Formulation of Nifurtimox
by Zacks Equity Research
Bayer (BAYRY) files application to the FDA for the new formulation of nifurtimox to improve the body-weight adjusted dosing in pediatric Chagas patients.
Lilly's NDA for Selpercatinib Gets FDA's Priority Review
by Zacks Equity Research
Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.
Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up
by Zacks Equity Research
Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.
Eli Lilly (LLY) Tops Q4 Earnings & Sales, Keeps 2020 View
by Kinjel Shah
Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.
5 Top Non-Tech Earnings Charts
by Tracey Ryniec
It's not all about technology or social media companies. These 5 companies are also in the earnings spotlight.
Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review
by Zacks Equity Research
The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More
by Zacks Equity Research
Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
Merck's Dificid Gets FDA Approval in Pediatric Indication
by Indrajit Bandyopadhyay
The FDA grants approval to Merck's (MRK) two regulatory applications seeking expanded approval for its antibacterial medicine, Dificid.
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
by Zacks Equity Research
AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
Lilly's Olumiant Meets Primary Goal in Dermatitis Study
by Zacks Equity Research
Eli Lilly (LLY) and partner Incyte's Olumiant meets primary endpoint in atopic dermatitis in a late-stage study.
Dr. Reddy's (RDY) Q3 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings (excluding impairment charge) increase year over year in the third quarter of fiscal 2020.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $139.07 in the latest trading session, marking a -1.52% move from the prior day.
J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children
by Zacks Equity Research
Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.
The Zacks Analyst Blog Highlights: Pfizer, Wells Fargo, SAP, salesforce.com and Eli Lilly
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Wells Fargo, SAP, salesforce.com and Eli Lilly
Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review
by Zacks Equity Research
Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FTCS
Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Wells Fargo (WFC) and SAP SE (SAP).